Medicina (Buenos Aires)
versión On-line ISSN 1669-9106
Medicina (B. Aires) v.62 n.4 Ciudad Autónoma de Buenos Aires jul./ago. 2002
Aflatoxin B1content in patients with hepatic diseases
Clara López, Laura Ramos, Lucía Bulacio, Silvana Ramadan, Fernanda Rodríguez
Centro de Referencia de Micología (CEREMIC). Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario.
Postal address: Dra. Clara E. López, Olivé 1469. (2000) Rosario. ARGENTINA.
Fax: (54-11) 0341-4307624. e-mail: email@example.com
Aflatoxins are toxic metabolites of some Aspergillus flavus, A. parasiticus and A. nomius strains that occur in many foods and feeds. There are four major natural occurring aflatoxins: B1, B2, G1 and G2. These toxins can cause illness in human beings and animals. Aflatoxin B1 is the most abundant and toxic member of the family, and it is also the most potent hepatocarcinogen known. In order to estimate the potential human health risk of AFB1, it is useful to measure blood concentration. The presence of aflatoxin B1 in patients was evaluated by high-performance liquid chromatography, in serum samples, obtained from 20 patient volunteers with hepatic disease. Out of the 20 patients, the presence of AFB1 was detected in only one of them, in a concentration of 0.47 ng/cm3. Nevertheless, this result should draw the attention of control organizations in Argentina to the need for a thorough food and feed inspection.
Key words: Aflatoxin B1; Hepatic diseases; Serum samples; HPLC
Aflatoxina B1 en pacientes con enfermedades hepáticas. Las aflatoxinas son metabolitos tóxicos producidos por cepas de Aspergillus flavus, A. parasiticus y A. nomius, presentes en alimentos y piensos. Las cuatro aflatoxinas principales son: aflatoxina B1, B2, G1 y G2. Dichas toxinas pueden causar enfermedades tanto en seres humanos como en animales. La aflatoxina B1 es la más abundante y la más tóxica del grupo y es también el más potente hepatocarcinógeno conocido. El objetivo de este trabajo fue detectar la presencia de aflatoxina B1 en sangre humana para estimar el riesgo potencial de la salud. La determinación de aflatoxina B1 fue realizada por cromatografía líquida de alto rendimiento, en suero de 20 pacientes voluntarios con enfermedades hepáticas. En sólo uno de estos pacientes se detectó la presencia de aflatoxina B1, en una concentración de 0.47ng/cm3. Estos resultados deberían ser tenidos en cuenta por los responsables de la vigilancia y control de los alimentos en la Argentina.
Palabras clave: Aflatoxina B1; Enfermedades hepáticas; Suero; HPLC.
Aflatoxins are secondary metabolites produced by Aspergillus flavus, A. parasiticus and A. nomius. There are four naturally occurring aflatoxins: aflatoxin B1 (AFB1), B2, G1 and G2, all of them toxic, mutagenic and carcinogenic compounds, especially AFB1. The World Health Organization has recently classified AFB1 as a class 1 carcinogen1. Aflatoxins have been detected frequently in samples of corn, peanuts, cottonseeds, rice and other foodstuffs1-3. In Argentina, these mycotoxins have been detected in nuts, peanuts4,5 and corn flour6. These data indicate that mycotoxins can enter the human diet via contaminated foodstuffs.
AFB1 is a well-documented hepatocarcinogen in animals, although species susceptibility varies greatly. In human beings, aflatoxins have been implicated in the etiology of hepatocellular carcinoma (HCC). Ecological studies performed in Africa and Southeast Asia have revealed a significant correlation between the aflatoxin exposure and incidence of human HCC7,8. The hypothesis that AFB1 has a causative role in the etiology of human HCC is also supported by some other findings in areas with high aflatoxin ingestion. A large fraction of the tumor tissue and adjacent non-malignant liver tissues from HCC patients contained an AGG to AGT mutation at codon 249 of the p53 tumor suppressor gene9. This mutation is also induced in cultured Hep G2 human hepatocytes exposed to AFB110 .
Since aflatoxin contaminated foodstuffs have been found in Argentina, we thought that it was important to determine whether or not detectable levels of AFB1 are present in human serum samples in our country. In order to estimate the potential human health risk of AFB1, we considered that it was important to measure its blood concentration. Several methods have been used in order to analyze feeds, foods and body fluids (human and animal plasma, serum, milk, etc). Analytical procedures, such us high performance liquid chromatography (HPLC), thin layer chromatography (TLC) and enzymoimmu-noassay (ELISA), are commonly used.
The aim of this study was to evaluate the presence of AFB1 in serum samples from twenty patient volunteers with hepatic disease.
Material and Methods
Patients and control sample
Ten milliliters of blood were taken from each of the twenty patients (Hospital Provincial del Centenario), all of whom suffered from hepatic diseases (hepatitis, cirrhosis or others and so on), and were from Rosario (Argentina).
A number of twenty-five normal healthy adult volunteers made up the control group. The patients were between 42 and 64 years old, and 65% were male.
All procedures using human samples were performed in accordance with the ethical standards established by the University of Rosario.
Each subject completed a questionnaire, which included questions on age, sex, occupation (i.e. peasant, factory worker, office employee, private business), residence (close to or far away from silos), hepatitis B antigen (HBsAg) status (carrier or non-carrier), smoking habits (smoking or non-smoking) and alcohol consumption.
The serum samples were stored at 4°C for up to one week.
Serum samples in duplicate were extracted using chloroform and hexane. Extracts were evaporated to dryness under a stream of nitrogen, stored at 4°C for up to one week, and analyzed by HPLC, method according to Lamplugh11.
HPLC was performed using a Hewlett Packard HPLC Series 1050 with autosampler and fluorescence detector. The detector was programmed to have excitation/emission wavelengths at 366 and 418 nanometers (nm) respectively. The column was a reverse-phase Hypersil C18 column (150 mm x 4.6 mm). A volume of 20 mm3 of sample was injected into the instrument. The mobile phase consisted of a mixture of methanol-water-acetonitrile (25:25:50 v/v) eluted at a flow rate of 0.8 cm3/min.
Calibration curve and blank serum samples were analyzed to detect fluorescent compounds, which might interfere with AFB1 analyses.
The identity confirmation test was performed with a serum sample spiked with a final concentration of standard Sigma A6636 of 1.6 ng/cm3 and processed following the same protocol used with patients' samples.
Data concerning the presence of AFB1 in serum and control samples, are summarized in Table 1.
Out of the 20 patients' samples, the presence of aflatoxin B1 was detected in only one of them (Fig. 1-a, Fig. 1-b). The concentration in this sample was 0.47 ng/cm3. It was determined by comparing the peak height obtained with the calibration curve obtained from spiked serum samples (Fig. 1-c).
Storage of extracts of spiked sera as well as extracts obtained from patients' samples at 4°C for periods up to one week did not affect the recovery of AFB1.
The limit of detection for AFB1 determined by analyz-ing serum samples spiked with decreasing concentrations of aflatoxin B1, was 250 pg/cm3.
No fluorescent compounds were detected in blank serum samples. The waste solvents were also analyzed, showing no presence of AFB1. The patient whose serum contained AFB1 suffered from cirrhosis.
Table 2, shows the characteristics of the patients and control group, whose samples were analyzed according to occupation, residence, HBsAg carrier condition, smoking and alcohol consumption habits.
The patient whose serum contained aflatoxin B1 was 53 years old, masculine, lived far away from silos, suffered from cirrhosis; he was HBsAg-negative, a non-smoker and an alcohol drinker.
A number of clinical reports on acute aflatoxicosis and its relation to chronic hepatic injury and hepatocellular carcinoma due to aflatoxin contaminated food have appeared12-14 in the world. Aflatoxins are also known to affect and suppress the immune responses of experi-mental animals15, 16. However, no previous report has been made to our knowledge of the detection of aflatoxins in Argentinian patients.
Under natural conditions, exposure to the aflatoxins may occur orally (by food ingestion) and by tracheal and bronchial absorption (by the inhalation of contaminated dust). It is a well-documented fact that absorption following oral exposure is complete17, 18. After absorption, the AFB1 is transported via the blood and not via the lymphatic system19, 20. Hsieh and Wong found that over 50% of radio-labelled toxin disappeared from the duodenum within one hour, appearing in the venous blood as water-soluble metabolites, protein adducts and free toxin21. Protein adducts (in which the AFB1 is linked to the lysine component of serum albumin) represented over 50% of the total radio-activity; the water-soluble meta-bolites occurred in only minor quantities and free AFB1 represented less than 33% of the labelled material22, 23. This could explain the low concentration detected in the patient in question.
The finding of AFB1 in the human serum in an Argentinian patient, to the best of our knowledge, is the first such report. However, it could not reach significance probably due to the small number of samples involved.
The finding of only one patient with AFB1 in serum, did not allow to study the correlation between mycotoxi-cosis and some other factors, such as age, sex, hepatic disseases, habits, etc.
The patient with positive result neither was a peasant nor lived close to silos, so we can conclude that the patient was not exposed to aflatoxins by contaminated dust. The detection of AFB1 in his serum may suggest that the patient ate food contaminated with this micotoxin.
Detection of the contamination of food products by filamentous fungi excludes them from the food chain in developed countries. Unfortunately, this action is infre-quent in many developing countries, and contaminated foodstuffs enter into the diet. If it were possible, it would be ideal to avoid its entry into commerce in every country.
Since some toxins may persist even when the fungi are no longer there, it is important to consider the fact that in foodstuffs it must beenanalyzed not only for the presence of toxigenic fungi but also for the presence of mycotoxins. Besides, the presence of toxigenic fungi in foods must alert the autorities about a potential hazard in foodstuffs that are not immediately consumed and could be stored in inadequate conditions.
Our data indicate that, as in many other countries, AFB1 is present in food or feed products available in Argentina, and in order to protect the health of consumers, their regular control is desirable.
1. Tseng T. Recent aspects of aflatoxin Research in Taiwan. J of Toxicology- Toxin Reviews 1994; 13: 229-41. [ Links ]
2. Ruston I. Aflatoxin in food and feed: Occurrence, legislation and inactivation by physical methods. Food Chemistry 1997; 59: 57-67. [ Links ]
3. Galvano F, Galofaro V, Galvano G. Occurrence and stability of aflatoxin M1 in milk and dairy products: A world wide review. J of Food Protection 1996; 59: 1070-9. [ Links ]
4. López C, Ramos L, Bulacio L, Yujnovsky F. Determination of aflatoxins in nuts, peanuts, almonds and hazelnuts. Identification of producing fungi. Revista Brasileira de Toxicologia 2000; 13: 51-4. [ Links ]
5. Dalcero, A., Etcheverri, M., Torres, A., Chulze, S., Tapparelli, M., Minudri, D. Estudio del grupo Aspergillus flavus y detección de aflatoxinas en maní de la provincia de Córdoba, Argentina. Abstract II Congreso Latinoamericano de Micotoxicología. Maracay, Venezuela. 1997, pp. 84-85. [ Links ]
6. Garbini A, Galli S, Tomchinsky E, et al. Aflatoxinas: Control en alimentos a base de harina de maíz. Congreso Latinoamericano de Micotoxicología. Maracay, Venezuela. 1997; p. 86. [ Links ]
7. Chen C, Wang L, Lu S, et al. Elevated aflatoxin exposure and risk of hepatocellular carcinoma. Hepatology 1996; 24: 38-42. [ Links ]
8. London W, Mc Glynn K, Buetow P, et al. Viral, host and environmental risk factors for hepatocellular carcinoma: A prospective study in Haimen city, China. Intervirology 1995; 38: 155-61. [ Links ]
9. Aguilar F, Harris C, Sun T, Hollstein M, Cerruti P. Geographic variation of p53 mutational profile in nonmalignant human liver. Science 1994; 264: 1317-9. [ Links ]
10. Aguilar F, Perez Hussain S, Cerruti P. Aflatoxin B1 induces the transversion of G®T in the codon 249 of the tumor suppressor gene in human hepatocytes. Proc. Natl. Acad. Sci. USA 1993; 90: 8586-90. [ Links ]
11. Lamplugh S.M. Comparison of three methods for the extraction of aflatoxins from human serum in combination with high performance liquid chromatographic assay. Journal of Chromatography 1983; 273: 442-4. [ Links ]
12. Stora C, Dvorackova I, Ayraud N. Characterization of aflatoxin B1 (AFB1) in human liver cancer. Research Commun Chem Pathol Pharmac, 1981; 31: 77-84. [ Links ]
13. Van Rensburg SJ, Cook-Mozaffari P, Van Schalkwyk DJ, Van Watt JJ, Vincent TJ, Purchase IF. Hepatocellular carcinoma and dietary aflatoxin in Mozambique and Transkei. Br J Cancer 1985; 51: 713-26. [ Links ]
14. Krishnamachari KAVR, Bhat RV, Nagarajan V, Tilak TBG. Hepatitis due to aflatoxicosis; an outbreak in Western India. Lancet 1975; I-2: 1061-3. [ Links ]
15. Jakab GJ, Hmieleski RR, Zarba A, Hemenway DR, Groopman JD. Respiratory aflatoxicosis: Supression of pulmonary and systemic host defenses in rats and mice. Toxicol Appl Pharmacol 1994; 125: 198-205. [ Links ]
16. Pier AC. Major biological consequences of aflatoxicosis in animal production. J Anim Sci 1992; 70: 3964-7. [ Links ]
17. Wogan GN, Edwards GS, Shank RC. Excretion and tissue distribution of radioactivity from aflatoxin B1 14C in rats. Cancer Research 1967; 27: 1729-36. [ Links ]
18. Dalezios JI, Hsieh DPH, Wogan G.N. Excretion and meta-bolism of orally administered aflatoxin B1 by rhesus monkys. Food and Cosmetics Toxicology 1973; 11: 605-16. [ Links ]
19. Wilson R, Ziprin R, Ragsdale S, Bussbe D. Uptake and vascular transport of ingested aflatoxin. Toxicology Letters 1985; 29: 169-76. [ Links ]
20. Kumagai S. Intestinal absorption and excretion of aflatoxin in rats. Toxicology and Applied Pharmacology 1989; 97: 88-97. [ Links ]
21. Hsieh DPH, Wong JJ. Pharmacokinetics and excretion of aflatoxins. In: Eaton, D.L., Groopman, J.D. (Eds), The Toxicology of Aflatoxins: Human Health, Veterinary and Agricultural Significance, New York: Academic Press, 1994; pp. 73-88. [ Links ]
22. Coker RD. Mycotoxins and their control: constraints and opportunities. Bulletin 73. 1997; Natural Resources Institute. The University of Grenwich. [ Links ]
23. Sotomayor RE, Sahu S, Washington M, Hinton DM, Chou M. Temporal patterns of DNA adduct formation and glutathion S-transferase activity in the testes of rats fed aflatoxin B1: A comparison with patterns in the liver. Environmental and Molecular Mutagenesis 1999; 33: 293-302. [ Links ]